Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.

Oncologist · 2023 · PMC9847563 · PMID 35881028

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Scales with nominally significant 95% CIs for HRs included the FKSI-DRS total score and the EORTC QLQ-C30 emotional functioning, social functioning, dyspnea, insomnia, and financial difficulties scales.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.